Daniel E. Everitt

TB Alliance — United States

Medicine · Health Sciences

33h-index5.8kcitations70works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(21), Pneumonia and Respiratory Infections(9), Mycobacterium research and diagnosis(9), Glaucoma and retinal disorders(6), Pneumocystis jirovecii pneumonia detection and treatment(6)

Publications70 total

Introducing BPaL: Experiences from countries supported under the LIFT-TB project
PLoS ONE·2024· 9 citedOpen Access
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
New England Journal of Medicine·2022· 511 citedOpen Access
Male reproductive hormones in patients treated with pretomanid
The International Journal of Tuberculosis and Lung Disease·2022· 6 citedOpen Access
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
BMJ Open·2021· 29 citedOpen Access
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
The International Journal of Tuberculosis and Lung Disease·2021· 30 citedOpen Access
Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis
Antimicrobial Agents and Chemotherapy·2021· 29 citedOpen Access
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
The International Journal of Tuberculosis and Lung Disease·2021· 61 citedOpen Access
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
Clinical Pharmacology in Drug Development·2020· 9 citedOpen Access
An Exposure-Response Perspective on the Clinical Dose of Pretomanid
Antimicrobial Agents and Chemotherapy·2020· 10 citedOpen Access
Clofazimine pharmacokinetics in patients with TB: dosing implications
Journal of Antimicrobial Chemotherapy·2020· 64 citedOpen Access
Reply to Kim et al., “Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment”
Antimicrobial Agents and Chemotherapy·2020Open Access
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
New England Journal of Medicine·2020· 964 citedOpen Access
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Antimicrobial Agents and Chemotherapy·2020· 38 citedOpen Access
A Partially-Randomised Phase 3 Trial of Pretomanid, Moxifloxacin and Pyrazinamide in Combination for the Treatment of Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis
SSRN Electronic Journal·2020· 1 citedOpen Access
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
The Lancet Respiratory Medicine·2019· 143 citedOpen Access
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
Antimicrobial Agents and Chemotherapy·2019· 31 citedOpen Access
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy·2019· 33 citedOpen Access
Sterile Tuberculous Granuloma In a Patient with XDR-TB Treated with Bedaquiline, Pretomanid and Linezolid
2019· 1 cited
Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System
Journal of Clinical Microbiology·2016· 28 citedOpen Access
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
The International Journal of Tuberculosis and Lung Disease·2016· 17 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Carl M. Mendel(11), Andreas H. Diacon(9), Jerry Avorn(9), Melvin Spigelman(8), Rodney Dawson(8), Francesca Conradie(6), Mengchun Li(6), Mary Ann Mascelli(6), Angela M. Crook(5), Charles Pendley(5), Diane K. Jorkasky(5), Jerry Nedelman(5), Erica Egizi(4), Genevieve H. Wills(4), Christo van Niekerk(4), Ebrahim Variava(4), Amour Venter(4), Stephen B. Soumerai(4), Jerry H. Gurwitz(4), Mark Monane(4)